Jazz Pharma to buy Celator in $1.5 bln deal

May 31 (Reuters) - Ireland-based Jazz Pharmaceuticals Plc will buy Celator Pharmaceuticals Inc in a deal valued at about $1.5 billion, to gain access to Celator's investigational product in development for treating acute myeloid leukemia.